Cidara Therapeutics Shares Rise on Positive Influenza Trial Results

Cidara Therapeutics shares are trading higher after the company announced successful Phase 2b trial results for CD388, demonstrating significant efficacy in preventing symptomatic influenza and showing good tolerability.